DOCSLIB.ORG

En Busca Del Opioide Ideal. Nuevas Moléculas

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
En Busca Del Opioide Ideal. Nuevas Moléculas En busca del opioide ideal. Nuevas moléculas Luz Romero PhD Sebastià Videla MD PhD Barcelona, 1 de diciembre de 2017 Guión EN BUSCA DEL OPIOIDE IDEAL ESTADO ACTUAL DE LA INVESTIGACIÓN EN OPIOIDES Ø Analgesia: • “Farmacología nueva” • Combinaciones Ø Indicaciones diferentes a analgesia: • “Farmacología nueva”: Antagonistas opioides • Combinaciones (antagonistas opioides + otros) Guión EN BUSCA DEL OPIOIDE IDEAL ESTADO ACTUAL DE LA INVESTIGACIÓN EN OPIOIDES Ø Analgesia: • “Farmacología nueva” • Combinaciones Ø Indicaciones diferentes a analgesia: • “Farmacología nueva”: Antagonistas opioides • Combinaciones (antagonistas opioides + otros) δ κ Opioid Receptor Types µ Opioid NOP Current NC-IUPHAR Previous Presumed Recommended Nomenclature Effects Endogenous Ligands Nomenclature (2000) (1996) Analgesia, sedation, euphoria, -endorphin (not selective) β vomiting, respiratory depression, enkephalins (not selective) OP3 constipation, pruritus, anorexia, µ, mu, or MOP endomorphin-1 (tentative) urinary retention, miosis, physical endomorphin-2 (tentative) dependence enkephalins (not selective) Analgesia (without many adverse OP1 δ, delta, or DOP β-endorphin (not selective) effect), not well understood dynorphin A Analgesia, respiratory depression, OP2 dynorphin B κ, kappa, or KOP dysphoria α-neoendorphin Nociceptin/orphanin FQ OP4 Analgesia and morphine tolerance NOP (ORL-1) (N/OFQ) Localization of opioid receptors OPIOIDE → afinidad selectiva por los receptores opioides centrales y periféricos ⇒ inhiben: 1) la transmisión de la entrada nociceptiva, y 2) la percepción del dolor Localization of opioid receptors OTRAS ACCIONES → efectos adversos Ideal opioid ? Action Receptor Benefit Pain inhibition µ, δ, κ, NOP Addiction µ > κ Euphoria and sedation µ Dysphoric and psychotomimetic κ Physical dependence µ > κ; δ? Tolerance µ, κ, δ Respiratory depression µ, δ Muscle Pain / Stiffness µ Miosis µ, κ Nausea, vomiting µ, κ, δ Risk Gastrointestinal motility µ, δ? Bladder motility µ Diuresis: Inhibition µ Stimulation κ Bradycardia µ > δ = κ Hypotension δ = κ > µ Endocrine actions: Prolactin release µ GH release δ > κ ACTH release µ, κ ADH inhibition κ LH Inhibition µ, δ Ideal opioid – ‘holy grail’ ↑ Benefit-Risk relationship = = Benefit ↓ Risk Nature. 2016 Sep 8;537(7619):170-171. Ideal opioid – ‘holy grail’ ↑ Benefit-Risk relationship = = Benefit ↓ Risk Action Receptor Benefit Pain inhibition µ, δ, κ, NOP Addiction µ > κ Respiratory depression µ, δ Risk Nausea, vomiting µ, κ, δ Constipation µ, δ? Tolerance µ, κ, δ Why investigate in opioids ? Why investigate in opioids ? 1.- Fracaso de la investigación clínica en demostrar la eficacia de nuevos mecanismos de acción / nuevas dianas terapéuticas implicados en analgesia Why investigate in opioids ? Why investigate in opioids ? Other a Mechanism of Action Other b Alpha a. MC SuGA TREK FGF Other TRPs OREs PDEs H1 MMPs Other GFs Antisense Other AD GCH TLRs MAPK H+ sens. ASICs PTH ILs TNF NKs Muscar. ETs NGF NTs Other CIT VIP CC / CXCRs SST CRFs Glutamate NE-uptake BDNF σ1 Gal NO PXs GABA NMDA Adenosine FAAH GDNF CCK HCNs ORL-1 Bradykinin Potassium Calcium GL O. Kinases VRs mGluRs AMPA / K CBs 5-HT NPY HIST COX Gabapentinoids Sodium NNRs ACh CGRP NE / NA Opioids BSAEDs Prostanoids Project Selection Preclinical & Clinical Validation Potential Competitive Advantages; Value Added Product Profile Discontinued pain drugs between 2009-2014 Phase I 34% Phase II 56% Phase III 9% 1. BVT-115959 (Adenosine A2a) 1. BL-1021 (Sodium channels) 1. Bicifadine (NA/5-HT transpoters) 2. AZD-2066 (mGluR5) 2. NCX-1236 (Nitric Oxide) 3. AZD-2516 (mGluR5) 2. Esreboxetine (NA transporter, Alpha 2) 4. LY-545694 (Glu Kainate) 3. PF-3557156 (PDE 7A) 3. MoxDuo (morphine + oxycodone) 5. PH-797804 (P38 kinase) 4. SEP-227900 (D-amino-acid oxidase) 6. PF-4480682 (GABA A, PDE 5) 7. KHK-6188 (CB2) 5. SEP-228432 (DA/NA/5-HT transporters) 8. Placulumab (TNF alpha) 6. NSD-644 (DA/NA/5-HT transporters) 9. AZD-1940 (CB1/2) 10. Ataciguat (Guanylate cyclase) 7. SAR-114137 (Cathepsin S/K) 11. ADL-5859 (Opioid Delta) 8. GPI 5693 (Glutamate Carboxypeptidase II) 12. Radiprodil (Glu NMDA) 13. Sofinicline (Nicotinic alpha4, beta2) 9. AZD 6088 (Muscarinic M1) 14. AZD-2423 (Chemokine CCR2) 10. BI-660848 (Undefined) 15. SC-75416 (COX-2) 16. ASP-3652 (Undefined) 11. SAR-407899 (Rho-kinase) 17. Indantadol (MAO A/B; Glu NMDA) 18. Z-160 (Calcium channel N-type) Sponsor terminated 1 Strategic 4 Unspecified 15 REASON FOR DISCONTINUATION: Adverse effects 2 Lack of efficacy/Low efficacy 8 32 drugs Low efficacy + safety 1 Pharmaceutical characteristics 1 Adapted from: Expert Opin Investig Drugs. 2015;24(12):1631-46. Discontinued pain drugs between 2015-2016 Phase I 40% Phase II 47% Phase III 13% 1. ALKS-7106 (Opioid receptor agonist) 1. PF-05089771 (Nav1.7 blocker) 1. Fulranumab (recombinant IgG2 2. ASP-9226 (Undefined) 2. PF-489791 (PDE-5 inhibitor) anti-NGF mAb) 3. LY-2969822 (mGlu2/3 agonist) 3. Senrebotase (Endopeptidase 2. Clonidine (topical gel) (Alpha 2 4. PHE-377 (TRPV1 antagonist) modulator) agonist) 5. ODM-108 (TRPA1 inhibitor) 4. 10% lidocaine (vaginal gel) (Na 6. BIA-102474 (FAAH inhibitor) channel inhibitor) 5. ASP-8477 (Undefined) 6. Dexisometheptene (Imidazoline I1R agonist) 7. AZD-5213 (H3 receptor antagonist) Sponsor terminated 0 Strategic 2 Unspecified 7 REASON FOR DISCONTINUATION: Adverse effects 1 Lack of efficacy/Low efficacy 4 15 drugs Low efficacy + safety 1 Pharmaceutical characteristics 0 Source: Integrity, Cortellis, Companies website. Discontinued opioid drugs between 2010-2016 Phase I 19% Phase II 44% Phase III 31% 1. JDTic (Opiate dependence) 1. AZD-2327 (Anxiety; Depression) 1. Bevenopran (Constipation) 2. AZD-7268 (Anxiety; Depression) 2. KRP-110 (Pruritus) 2. Fentanyl (inhaled TAIFUN) 3. PF-4856880 (NeP; Pain) 3. MT-7716 (Alcoholism) 4. PF-4856881 (Pain; Postherpetic (Cancer pain) neuralgia) 3. Fentanyl (transdermal matrix 5. Buprenorphine hemiadipate patch) (Cancer pain; Pain) hydrochloride (oral tablet, 4. Tramadol (orally Discovery 6% formulated with abuse-deterrent naloxone), (Opiate dependence) disintegrating tablet) 6. Fentanyl (inhaled, liposomal), (Premature ejaculation; 1. Tramadol + PDE5 inhibitor (Cancer pain; Pain) Erectile dysfunction) 7. LY-2940094 (Alcoholism; Major (Premature ejaculation; 5. MoxDuo (morphine + depressive disorder) Erectile dysfunction) oxycodone) DELTA agonist 4 DELTA antagonist; MU antagonist 1 KAPPA antagonist 1 MU agonist 6 TARGET-BASED ACTIONS MU agonist; PDE 5 inhibitor 1 16 drugs MU antagonist 1 NOP agonist 1 NOP antagonist 1 Source: Integrity, Cortellis, Companies website. Why investigate in opioids ? 1.- Fracaso nuevos mecanismos de acción en analgesia 2.- Los agonistas opioides continúan siendo hasta el momento los mejores analgésicos de que disponemos Why investigate in opioids ? 1.- Fracaso nuevos mecanismos de acción en analgesia 2.- Agonistas opioides → los mejores analgésicos 3.- Los efectos analgésicos de los opioides son debidos a la activación del sistema opioide endógeno (SOE) ⇒ principal mecanismo inhibitorio que modula de forma fisiológica la transmisión nociceptiva en mamíferos Why investigate in opioids ? 1.- Fracaso nuevos mecanismos de acción en analgesia 2.- Agonistas opioides → los mejores analgésicos 3.- Sistema opioide endógeno 4.- https://www.google.es/search?q=dolar+dinero&espv=2&biw=1536&bih=716&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjwye- v7pTSAhXDcBoKHcLBBNMQ_AUIBigB#imgrc=854OLB6sp4hFlM. Opioid Consumption by Countries — ME minus Methadone, mg/capita, 2014 Pain & Policy Studies Group (PPSG) - International Narcotics Control Board (INCB) The graph shows the aggregate amount of 6 principal opioids countries consumed in morphine equivalence as it relates to their Human Development Index score Fentanyl Hydromorphone Morphine Oxycodone Pethidine https://ppsg.medicine.wisc.edu/chart. Opioid Consumption in Spain Consumo extrahospitalario - Sistema Nacional de Salud Oxycodone Consumption Source: QuintilesIMS, Disease Insights, Chronic Pain, Oct 2016 Launched drugs acting on opioid receptors Source: Integrity, Cortellis. Guión EN BUSCA DEL OPIOIDE IDEAL ESTADO ACTUAL DE LA INVESTIGACIÓN EN OPIOIDES Ø Analgesia: • “Farmacología nueva” • Combinaciones Ø Indicaciones diferentes a analgesia: • “Farmacología nueva”: Antagonistas opioides • Combinaciones (antagonistas opioides + otros) Searching for the ideal opioid - ANALGESIA Novel pharmacology: 1. MOP agonist: Biased µ-opioid receptor ligands 2. Mul>-mechanis>c ligands 3. KOP / NOP agonist Combinaons: 1. COMBOs: OPIOIDS and others (NSAIDs, benzodiazepines) 2. COMBOs: OPIOIDS AGONIST and OPIOIDS ANTAGONIST 3. COMBOs: OPIOIDS ANTAGONIST and OTHERS Searching for the ideal opioid: Novel Pharmacology 1. MOP agonist: Biased µ-opioid receptor ligands 7-transmembrane G-protein coupled receptor Reduced neurotransmiTer release Intracellular changes occurring following the binding of an opioid agonist to a G-protein coupled opioid receptor Rev Pain. 2008 Mar;1(2):2-5. / Br J Pain. 2012 Feb;6(1):11-6. Searching for the ideal opioid: Novel Pharmacology 1. MOP agonist: Biased µ-opioid receptor ligands ↑ Benefit-Risk relationship = = Benefit ↓ Risk Searching for the ideal opioid: Novel Pharmacology 1. MOP agonist: Biased µ-opioid receptor ligands Label: pain Pain Pruritus IDBS- Pulmonary Phase D Hypertensio n TRV130 (Oliceridine III MU ago biased X ) MU ago, slow NKTR-181 III X brain entry Searching for the ideal opioid: Novel Pharmacology 1. MOP agonist: Biased µ-opioid receptor ligands Oliceridine (TRV130): Biased µ-opioid agonist Be#er
Load more

Recommended publications
  • Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
    REVIEW ARTICLE published: 01 February 2013 doi: 10.3389/fphar.2013.00007 Drug development for the irritable bowel syndrome: current challenges and future perspectives Fabrizio De Ponti* Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy Edited by: Medications are frequently used for the treatment of patients with the irritable bowel syn- Angelo A. Izzo, University of Naples drome (IBS), although their actual benefit is often debated. In fact, the recent progress in Federico II, Italy our understanding of the pathophysiology of IBS, accompanied by a large number of preclin- Reviewed by: Elisabetta Barocelli, University of ical and clinical studies of new drugs, has not been matched by a significant improvement Parma, Italy of the armamentarium of medications available to treat IBS. The aim of this review is to Raffaele Capasso, University of outline the current challenges in drug development for IBS, taking advantage of what we Naples Federico II, Italy have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions *Correspondence: that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective Fabrizio De Ponti, Pharmacology Unit, Department of Medical and Surgical drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS Sciences, University of Bologna, Via is a “functional disorder” where complex neuroimmune and brain-gut interactions occur Irnerio, 48, 40126 Bologna, Italy. and minimal inflammation is often documented:
    [Show full text]
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • Peripheral Kappa Opioid Receptor Activation Drives Cold Hypersensitivity in Mice
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice Manish K. Madasu1,2,3, Loc V. Thang1,2,3, Priyanka Chilukuri1,3, Sree Palanisamy1,2, Joel S. Arackal1,2, Tayler D. Sheahan3,4, Audra M. Foshage3, Richard A. Houghten6, Jay P. McLaughlin5.6, Jordan G. McCall1,2,3, Ream Al-Hasani1,2,3 1Center for Clinical Pharmacology, St. Louis College of Pharmacy and Washington University School of Medicine, St. Louis, MO, USA. 2Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy, St. Louis, MO, USA 3Department of Anesthesiology, Pain Center, Washington University. St. Louis, MO, USA. 4 Division of Biology and Biomedical Science, Washington University in St. Louis, MO, USA 5Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA 6Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, USA Corresponding Author: Dr. Ream Al-Hasani Center for Clinical Pharmacology St. Louis College of Pharmacy Washington University School of Medicine 660 South Euclid Campus Box 8054 St. Louis MO, 63110 [email protected] bioRxiv preprint doi: https://doi.org/10.1101/2020.10.04.325118; this version posted October 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Curriculum Vitae: Lin Chang
    CURRICULUM VITAE LIN CHANG, M.D. Professor of Medicine Vatche and Tamar Manoukian Division of Digestive Diseases David Geffen School of Medicine at UCLA PERSONAL HISTORY: Office Address: G. Oppenheimer Center for Neurobiology of Stress and Resilience 10833 Le Conte Avenue CHS 42-210 Los Angeles, CA 90095-7378 (310) 206-0192; FAX (310) 825-1919 EDUCATION: 1978 - 1982 University of California, Los Angeles, Degree: B.S. Biochemistry 1982 - 1986 UCLA School of Medicine, Los Angeles, Degree: M.D. 1986 - 1987 Internship: Harbor-UCLA Medical Center, Internal Medicine 1987 - 1989 Residency: Harbor-UCLA Medical Center, Internal Medicine 1989 - 1990 Research Fellowship: Harbor-UCLA Medical Center, Division of Gastroenterology 1990 - 1992 Clinical Fellowship: UCLA Integrated Program, Gastroenterology BOARD CERTIFICATION: ABIM: Internal Medicine 1989 Gastroenterology 1993, recertification 2014 PROFESSIONAL EXPERIENCE: 2006- present Professor of Medicine-in-Residence, Division of Digestive Diseases, David Geffen School of Medicine at UCLA 2000 - 2006 Associate Professor of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA 1997 - 2000 Assistant Professor of Medicine, Division of Digestive Diseases, UCLA School of Medicine Chang 2 1993 - 1997 Assistant Professor of Medicine-in-Residence, UCLA, Harbor-UCLA Medical Center 1992 - 1993 Associate Consultant, Mayo Clinic, Rochester, Minnesota, Department of Gastroenterology PROFESSIONAL ACTIVITIES: 2017 – present Vice-Chief, Vatche and Tamar Manoukian Division of Digestive
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Atopic Dermatitis - Ph 2 Trial Expected to Initiate Around Mid-Year 2019
    Targeting Pruritus With Novel Peripherally-Restricted Kappa Agonist Therapeutics Jefferies Healthcare Conference June, 2019 Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “estimate,” “expect,” “objective,” “ongoing,” “plan,” “propose,” “potential,” “projected”, or “up-coming” and/or the negative of these terms, or other comparable terminology intended to identify statements about the future. Examples of these forward-looking statements in this presentation include, among other things, statements concerning plans, strategies and expectations for the future, including statements regarding the expected timing of our planned clinical trials; the potential results of ongoing and planned clinical trials; future regulatory and development milestones for the Company's product candidates; the size of the potential markets that are potentially addressable for the Company’s product candidates, including the postoperative and chronic pain markets, and the pruritus market; the potential commercialization of Korsuva™ in the licensed territories; the potential benefits of license agreements entered by the Company, including the potential milestone and royalty payments payable to Cara; and the Company's expected cash reach. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Biased Signaling by Endogenous Opioid Peptides
    Biased signaling by endogenous opioid peptides Ivone Gomesa, Salvador Sierrab,1, Lindsay Lueptowc,1, Achla Guptaa,1, Shawn Goutyd, Elyssa B. Margolise, Brian M. Coxd, and Lakshmi A. Devia,2 aDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Physiology & Biophysics, Virginia Commonwealth University, Richmond, VA 23298; cSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; dDepartment of Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda MD 20814; and eDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143 Edited by Susan G. Amara, National Institutes of Health, Bethesda, MD, and approved April 14, 2020 (received for review January 20, 2020) Opioids, such as morphine and fentanyl, are widely used for the possibility that endogenous opioid peptides could vary in this treatment of severe pain; however, prolonged treatment with manner as well (13). these drugs leads to the development of tolerance and can lead to For opioid receptors, studies showed that mice lacking opioid use disorder. The “Opioid Epidemic” has generated a drive β-arrestin2 exhibited enhanced and prolonged morphine-mediated for a deeper understanding of the fundamental signaling mecha- antinociception, and a reduction in side-effects, such as devel- nisms of opioid receptors. It is generally thought that the three opment of tolerance and acute constipation (15, 16). This led to types of opioid receptors (μ, δ, κ) are activated by endogenous studies examining whether μOR agonists exhibit biased signaling peptides derived from three different precursors: Proopiomelano- (17–20), and to the identification of agonists that preferentially cortin, proenkephalin, and prodynorphin.
    [Show full text]
  • Structure of the Human Κ-Opioid Receptor in Complex with Jdtic
    ARTICLE doi:10.1038/nature10939 Structure of the human k-opioid receptor in complex with JDTic Huixian Wu1, Daniel Wacker1, Mauro Mileni1, Vsevolod Katritch1, Gye Won Han1, Eyal Vardy2, Wei Liu1, Aaron A. Thompson1, Xi-Ping Huang2, F. Ivy Carroll3, S. Wayne Mascarella3, Richard B. Westkaemper4, Philip D. Mosier4, Bryan L. Roth2, Vadim Cherezov1 & Raymond C. Stevens1 Opioid receptors mediate the actions of endogenous and exogenous opioids on many physiological processes, including the regulation of pain, respiratory drive, mood, and—in the case of k-opioid receptor (k-OR)—dysphoria and psychotomimesis. Here we report the crystal structure of the human k-OR in complex with the selective antagonist JDTic, arranged in parallel dimers, at 2.9 A˚ resolution. The structure reveals important features of the ligand-binding pocket that contribute to the high affinity and subtype selectivity of JDTic for the human k-OR. Modelling of other important k-OR-selective ligands, including the morphinan-derived antagonists norbinaltorphimine and 59-guanidinonaltrindole, and the diterpene agonist salvinorin A analogue RB-64, reveals both common and distinct features for binding these diverse chemotypes. Analysis of site-directed mutagenesis and ligand structure–activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for k-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human k-OR. The four opioid receptors, m, d, k and the nociceptin/orphanin FQ antidepressants, anxiolytics and anti-addiction medications14, whereas peptide receptor, belong to the class A (rhodopsin-like) c subfamily of a widely abused, naturally occurring hallucinogen—salvinorin A G-protein-coupled receptors (GPCRs)1 with a common seven- (SalA)—was also found to be a highly selective k-OR agonist15.
    [Show full text]